Deutsche Märkte schließen in 5 Stunden 25 Minuten

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
115,79-4,10 (-3,42%)
Börsenschluss: 04:00PM EDT
115,67 -0,12 (-0,10%)
Vorbörslich: 05:37AM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sektor(en)Healthcare
BrancheDiagnostics & Research
Vollzeitmitarbeiter10.590

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Jacob Thaysen Ph.D.CEO & Director796,63kN/A1975
Ms. Carissa L. RollinsChief Information Officer693,52kN/A1970
Mr. Charles E. Dadswell Esq.Senior VP & General Counsel1,03MN/A1959
Stephanie CamposPresidentN/AN/AN/A
Mr. Ankur DhingraChief Financial OfficerN/AN/A1976
Mr. Kevin Carl PegelsChief of Global OperationsN/AN/A1968
Mr. Scott EricksenVP & Chief Accounting OfficerN/AN/A1973
Dr. Steven Barnard Ph.D.Chief Technology OfficerN/AN/AN/A
Ms. Sallilyn SchwartzVice President of Investor RelationsN/AN/AN/A
Mr. Jakob WedelChief Strategy & Corporate Development Officer and CEO Chief of StaffN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Corporate Governance

Illumina, Inc.s ISS Governance QualityScore, Stand 1. Juli 2024, lautet 2. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 2, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.